Literature DB >> 21546631

Case report: treatment of chronic osteomyelitis.

Cameron R Wolfe1.   

Abstract

Presented is a case of chronic methicillin-resistant Staphylococcus aureus osteomyelitis, which was unsuccessfully treated with multiple courses of debridement and potent antibiotic therapies. Amputation of the patient's lower limb was believed to be the only option remaining. A compassionate access program, with approval from the US Food and Drug Administration and the institutional review board, enabled the patient to undergo a course of treatment with oral fusidic acid (CEM-102). The patient tolerated the drug well, with no significant toxicities noted to date. His infection improved rapidly, his flap healed, he has returned to work part-time, and he continues to take daily suppressive doses of oral CEM-102.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546631     DOI: 10.1093/cid/cir169

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

Review 1.  Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.

Authors:  Prabhavathi Fernandes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-04       Impact factor: 6.915

Review 2.  Advances in the local and targeted delivery of anti-infective agents for management of osteomyelitis.

Authors:  Caleb A Ford; James E Cassat
Journal:  Expert Rev Anti Infect Ther       Date:  2017-09-01       Impact factor: 5.091

Review 3.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 4.  A new strategy to fight antimicrobial resistance: the revival of old antibiotics.

Authors:  Nadim Cassir; Jean-Marc Rolain; Philippe Brouqui
Journal:  Front Microbiol       Date:  2014-10-20       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.